Group items tagged

The purpose of this Funding Opportunity Announcement (FOA) is to stimulate developmental research evaluating the effect of care planning on self-management of late effects of cancer therapy; adherence to medications, cancer screening, and health behavior guidelines; utilization of follow-up care; survivors' health and psychosocial outcomes. How organizational-level factors influence the implementation of care planning and its associated costs is also of interest. Specifically, the FOA aims to stimulate research that will: 1) develop and test metrics for evaluating the impact of survivorship care planning; 2) evaluate the impact of survivorship care planning on cancer survivors' morbidity, self-management and adherence to care recommendations, utilization of follow-up care; 3) evaluate effects of planning on systems outcomes, such as associated costs and impact on providers and organizations implementing the care planning; and 4) identify models and processes of care that promote effective survivorship care planning. The ultimate goal of this FOA is to generate a body of science that will inform the development and delivery of interventions that improve follow-up care for cancer survivors.

The purpose of this Funding Opportunity Announcement (FOA) is to stimulate research evaluating the effect of care planning on self-management of late effects of cancer therapy; adherence to medications, cancer screening, and health behavior guidelines; utilization of follow-up care; survivors' health and psychosocial outcomes. How organizational-level factors influence the implementation of care planning and its associated costs is also of interest. Specifically, the FOA aims to stimulate research that will: 1) develop and test metrics for evaluating the impact of survivorship care planning; 2) evaluate the impact of survivorship care planning on cancer survivors' morbidity, self-management and adherence to care recommendations, utilization of follow-up care; 3) evaluate effects of planning on systems outcomes, such as associated costs and impact on providers and organizations implementing the care planning; and 4) identify models and processes of care that promote effective survivorship care planning. The ultimate goal of this FOA is to generate a body of science that will inform the development and delivery of interventions that improve follow-up care for cancer survivors.

The Agency for Healthcare Research and Quality's (AHRQ) mission is to produce evidence to make health care safer, higher quality, more accessible, equitable, and affordable, and to work within the U.S. Department of Health and Human Services and with other partners to make sure that the evidence is understood and used. AHRQ's Center for Quality Improvement and Patient Safety (CQuIPS) is addressing patient safety and medication research by focusing on the safe usage of medications.  This perspective centers on how medications move through the health care system and how this systemic process can be improved so that patients are not harmed, while health care delivery is improved.  CQuIPS encourages the involvement of all members of the health care team, especially patients and families, nurses, pharmacists, technicians (pharmacy and medication administration technicians), health care administrators, risk managers, and physicians across all settings of care, including in the home. This FOA will fund investigative research demonstration projects that examine the effective implementation of processes, policies, and behaviors that support safe use of medication as well as its sustainment and dissemination.

The funding is offered in conjunction with the theme of the National Symposium on Academic Palliative Care Education and Research, Quality in Palliative Care: Fusing Education, Research and Practice, being held in San Diego from October 11 to October 12, 2018. Multiple grants ranging between $5,000 and $10,000 will be awarded at the symposium. The institute encourages proposals for innovative educational and/or research projects that will expand current or future workforce knowledge leading to improved care or enhanced quality of life for seriously or chronically ill people.

The American College of Cardiology's Accreditation Services help hospitals improve care for patients with acute coronary syndromes, heart failure, and atrial fibrillation. In 2016, ACC merged with the Society of Cardiovascular Patient Care (SCPC), a nonprofit organization dedicated to improving the care and outcomes of patients worldwide facing the same complications. To preserve the legacy of SCPC, an endowment was created to support future cardiovascular quality or performance improvement initiatives, particularly those that underscore the importance of accreditation. To advance that mission, ACCF is accepting proposals that support cardiovascular quality improvement of cardiovascular care and patient outcomes. Awards of up to $100,000 will support projects that contribute to the evidence base for accreditation; develop or evaluate cardiovascular quality initiatives that strengthen the accreditation process; provide opportunities for education that support quality or performance improvement projects; improve EMS systems of care in collaboration with community hospitals providing accreditation services; or provide public health education to improve community measures/outcomes related to early recognition of heart attack symptoms and appropriate action steps.

This notice solicits applications for a new three-year Special Projects of National Significance (SPNS) initiative entitled Capacity Building in the Ryan White HIV/AIDS Program to Support Innovative Program Model Replication. This Notice of Funding Opportunity (NOFO) responds to recent changes in the HIV epidemic and the need to find effective solutions that improve health outcomes along the HIV care continuum for people living with HIV (PLWH). During recent years, a number of innovative interventions have demonstrated effective responses that contribute to ending the HIV epidemic. Ryan White providers who have developed these evidence-informed interventions have produced replication manuals and other tools to assist organizations and jurisdictions interested in adapting and/or replicating such interventions. This NOFO seeks to build the capacity of Ryan White HIV/AIDS Program (RWHAP) recipients and subrecipients to replicate effective models of care., with a particular focus on RWHAP jurisdictions identified as disproportionately affected by HIV By building capacity and encouraging the implementation or replication of effective models of care, the RWHAP intends that these jurisdictions will bring recent innovations to scale, thus improving systems of care, reducing health disparities, improving outcomes along the HIV care continuum, and ultimately contributing towards meeting the goals and objectives of the National HIV/AIDS Strategy.

This notice solicits applications for the Health Center Program's Service Area Competition (SAC). The Health Center Program supports public and private nonprofit community-based and patient-directed organizations that provide primary health care services to the Nation's medically underserved populations. The purpose of the SAC NOFO is to ensure continued access to affordable, quality primary health care services for communities and vulnerable populations currently served by the Health Center Program. This NOFO details the SAC eligibility requirements, review criteria, and awarding factors for organizations seeking funding for operational support to provide primary health care services to an announced service area. For the purposes of this document, the term "health center" encompasses Health Center Program award recipients funded under the following subsections: Community Health Center (CHC - section 330(e)), Migrant Health Center (MHC - section 330(g)), Health Care for the Homeless (HCH - section 330(h)), and/or Public Housing Primary Care (PHPC - section 330(i)).

This Funding Opportunity Announcement (FOA) seeks to develop and test the next generation of interventions delivered through mobile health (mHealth) technology to improve diagnosis, linkage to care, retention in care, and viral suppression among youth living with human immunodeficiency virus (YLWH). This FOA supports planning for a clinical trial and can include a small pilot clinical trial that a) incorporates emerging and cutting edge technologies to enhance outcomes along the HIV care continuum, b) supports real-time clinical decision making, and c) facilitates effective long-term management of HIV. Critical to this FOA, proposed research should identify specific patient outcomes along the HIV care continuum that are expected to improve from technological approaches.

The FY17 JPC-1/MSIS TRANSfeR Award Program Announcement/Funding Opportunity is seeking research to determine whether the medical skill learned on a simulation system has a downstream beneficial effect to patients and/or the MHS in the real clinical world. The Program Announcement/Funding Opportunity seeks applications for research to demonstrate that simulation-based medical training has a measurable outcome on patient care. Previous T1 studies have shown improvement in skills in the simulated environment when deliberate practice and mastery learning (a set of group-based, individualized, learning strategies based on the belief that students will achieve a high level of understanding in a given area when given enough time) occur as part of training. The next set of studies should measure whether these same techniques translate to patient care and affect systems of care such as return-to-duty rates and morbidity and mortality statistics. Such research will involve taking the lessons learned in the laboratory and measuring outcomes in the patients who are cared for either in an operational environment or medical treatment facility. Historical patient outcome data does exist for the way medical professionals are trained now, so the variable being introduced in new studies would be simulation-based training.

This FOA aims to increase testing of populations most affected by chronic hepatitis B and/or hepatitis C; and training of health care providers. Part A is Networking & Capacity Building and Part B is Professional Education & Training. Part A strategies & activities should focus on leading and growing an existing national coalition that is geographically diverse, is in at least different 10 states; and whose members are actively involved in viral hepatitis. The aim is to share strategies, materials, and lessons learned among coalition members; provide technical assistance to conduct culturally competent educational outreach; build the capacity to test the target populations for chronic viral hepatitis; and engage members in implementing CDC’s national viral hepatitis educational campaign(s).Outcomes for Part A are: increased number and capacity of coalition members to deliver culturally competent educational outreach to target population; increased numbers of individuals tested for chronic viral hepatitis; and increased exposure to CDC’s national education campaign. Part B activities are: developing free, accurate, up-to-date, CE-accredited comprehensive web-based, on-demand hepatitis materials, resources and trainings for health care professionals. The outcomes for part B are increasing the knowledge and skills of health care professionals, including the ability to screen, diagnose, medically manage, and provide care to people with chronic viral hepatitis.

CDC announces supplemental funding for organizations that previously were awarded funding under the Notice of Funding Opportunity (NOFO) CDC-RFA-OE-17-1701. The purpose of his supplemental NOFO is to further strengthen the nation's capacity to carry out public health activities in the area of primary immunodeficiency diseases (PID) to widen the scope of the current grant, increase and improve physician education and public health awareness for/of PID. The intent is to increase the scope of the campaign to disseminate educational information on a national level to health care providers, educators, third-party payers, impacted families, and others who may help expedite clinical recognition and improve health outcomes for Americans with primary immunodeficiency diseases. The intended outcomes of this supplemental grant include increase in scope, in direct scale to conduct the following activities: - Development of materials and implementation of displays - Providers engage in education opportunities - Skills and knowledge of health care providers about primary immunodeficiency diseases increases - Improve integration of primary immunodeficiency diseases prevention into clinical care - Expedited clinical recognition of primary immunodeficiency diseases - Increase community and provider knowledge of primary immunodeficiency diseases - Increase the number of people appropriately diagnosed with primary immunodeficiency diseases - Increase access to care for people with primary immunodeficiency diseases. This announcement is only for non-research activities supported by CDC.

This NOFO aims to improve access to, coordination of, and continuity of health care for individuals with thalassemia or sickle cell disease which will lead to a decreased occurrence of transfusion-related complications, improved quality and increased length of life. These health care improvements will result from a multi-faceted approach that includes (1) identification of patients, families, communities, and providers who will benefit from increased knowledge about therapeutic transfusions and their potential complications, (2) development and dissemination of materials that will increase understanding of the diagnosis and management of these blood disorders, and (3) collection of biological specimens from individuals with thalassemia or sickle cell disease. This NOFO builds upon findings from the work completed as part of CDC-RFA-DD14-1406. In particular, (1) the difficulty in identifying any thalassemia patient in the U.S. and their health care provider prior to medical complications manifesting, other than those born in states where the condition is a part of the mandatory newborn screening panel, (2) the lack of standardized practices across, and sometimes within, clinical care settings and blood banks for transfusions of patients with thalassemia or sickle cell disease, (3) the need for dissemination of evidence- or consensus-based guidelines about best practices for transfusions, and (4) the room for improvement in increasing blood donation from communities most affected by thalassemia or sickle cell disease.

The American Cancer Society is accepting proposals for research projects with the potential to generate new knowledge of the effects of the United States healthcare system structure and the role of insurance in both access to and the outcomes of cancer screening, early detection, and treatment services. ACS is keenly interested in supporting rapid learning research on the effects of health policy changes on patients, providers, and health systems. This includes but is not limited to facilitators and barriers to care; unintended consequences; differential experiences and outcomes of patients seeking or receiving care; best practice models for quality care; and economic impact. Awards will not exceed $200,000 per year (direct costs) for up to four years. To be eligible, applicants must be affiliated with a nonprofit institution in the United States, one of its territories, or the Commonwealth of Puerto Rico; and be a U.S. citizen, non-citizen national, or permanent resident of the United States. Independent investigators at all stages of their career are encouraged to apply.

In an effort to support cardiovascular quality and performance improvement, the ACC provides funding opportunities that support future cardiovascular quality initiatives (QI) or performance improvement (PI), particularly those that highlight the importance of accreditation. Funding to support these projects is made possible by the Society of Cardiovascular Patient Care (SCPC), which was a nonprofit organization dedicated to improving the care and outcomes of patients worldwide with suspected acute coronary syndrome, heart failure, and atrial fibrillation through innovative cross-disciplinary processes. Its merger with the American College of Cardiology Foundation (ACCF) in 2016 provided an opportunity to leverage the accreditation strength of the SCPC into the large portfolio of services the ACCF offers. To preserve the legacy of the SCPC, an endowment was created to support future cardiovascular QI or PI, particularly those efforts that highlight the importance of accreditation. Focus areas of desired projects or proposals include those that support cardiovascular quality improvement of cardiovascular care and patient outcomes that: contribute to the evidence base for accreditation develop or evaluate cardiovascular quality initiatives that strengthen the accreditation process provide opportunities for education that support quality or performance improvement projects improve EMS systems of care in collaboration with community hospitals providing accreditation services provide public health education to improve community measures/outcomes related to early recognition of heart attack symptoms and appropriate action steps

The purpose of this U24 Funding Opportunity Announcement (FOA) is to support a bioinformatics group (BIG) that will analyze a set of asthma-specific common data elements (CDEs) retrospectively collected from the electronic health record data (EHR) of patients in the US whose asthma is managed by a primary care provider (PCP). Based on a large, nationally representative data set, the BIG will identify the current management practices (CMPs) of PCPs that result in the best asthma outcomes for specific groups of patients in different clinical settings or situations. The CMPs will be established by the BIG in collaboration with a clinical consultant team (CCT) with expertise in asthma and a primary care network (PCN), experienced in managing the primary care of patients. Following the BIG's analysis of retrospective data, the CCT and PCN will design and then conduct prospective clinical trials to compare the retrospectively identified CMPs in appropriate patients with asthma. At the conclusion of the clinical trials, the BIG will perform the data analysis for the assessment of the CMPs, refining any of the processes needed to analyze the asthma CDE data.

This NOFO will build on previous PEPFAR support under the HHS/CDC HIV treatment program in Côte d'Ivoire (CI) to ensure continuity of comprehensive HIV/AIDS services to an existing pool of clients receiving HIV/AIDS care, support, and/or treatment. The program will also continue expanding access to HIV/AIDS services while building the capacity of national structures and contributing to sustainable service delivery within the health sector in CI. Specifically, it serves to increase capacity and sustainability of the response toward controlling the HIV/AIDS epidemic by initially providing support for HIV service delivery aligning with PEPFAR geographic and programmatic pivots by local indigenous organizations and ultimately providing technical assistance to the national Ministry of Health and Public Hygiene (MSHP) to sustain and expand comprehensive HIV prevention, care, and antiretroviral therapy (ART) programs. The recipient(s) will combine a facility and community-based strategy to support HIV/AIDS services. At the end of the 5-year project period, the recipient(s) should be able to collect and evaluate program data that demonstrates improved quality of HIV prevention, care, and treatment services in CI and to transition activities to MSHP and/or local organizations to sustain a basic HIV service package.

The PRMRP Technology/Therapeutic Development Award (TTDA) is a product-driven award intended to provide support for the translation of promising preclinical findings into products for clinical applications, including prevention, detection, diagnosis, patient care, and/or quality of life, in at least one of the Congressionally directed FY13 PRMRP Topic Areas. Products in development should be responsive to the health care needs of military service members,Veterans, and/or beneficiaries. The product(s) to be developed may be pharmacologic agents (drugs or biologics), devices, and/or clinical guidance for standard of care. The Principal Investigator (PI) must provide a transitio

The Agency for Healthcare Research and Quality (AHRQ) is interested in funding a diverse set of projects that develop, test and evaluate various simulation approaches for the purpose of improving the safe delivery of health care. Simulation in health care serves multiple purposes. As a training technique, it exposes individuals and teams to realistic clinical challenges through the use of mannequins, task trainers, virtual reality, standardized patients or other forms, and allows participants to experience in real-time the consequences of their decisions and actions. The principal advantage of simulation is that it provides a safe environment for health care practitioners to acquire valuable experience without putting patients at risk. Simulation also can be used as a test-bed to improve clinical processes and to identify failure modes or other areas of concern in new procedures and technologies that might otherwise be unanticipated and serve as threats to patient safety. Yet another application of simulation focuses on the establishment of valid and reliable measures of clinical performance competency and their potential use for credentialing and certification purposes. The foremost aim of the announcement is to advance patient safety. Keeping this aim in mind, applications that address a variety of simulation techniques, clinical settings, provider groups, priority populations, and patient conditions are welcomed.

The goal of theBiomedical Engineering(BME)program is to provide research opportunities to develop novel ideas into discovery-level and transformative projects that integrate engineering and life sciences in solving biomedical problems that serve humanity in the long-term. BME projects must be at the interface of engineering and life sciences, and advance both engineering and life sciences. The projects should focus on high impact transformative methods and technologies. Projects should include methods, models and enabling tools of understanding and controlling living systems; fundamental improvements in deriving information from cells, tissues, organs, and organ systems; new approaches to the design of structures and materials for eventual medical use in the long-term; and novel methods for reducing health care costs through new technologies. The long-term impact of the projects can be related to fundamental understanding of cell and tissue function, effective disease diagnosis and/or treatment, improved health care delivery, or product development.

The goal of theBiomedical Engineering(BME)program is to provide research opportunities to develop novel ideas into discovery-level and transformative projects that integrate engineering and life sciences in solving biomedical problems that serve humanity in the long-term. BME projects must be at the interface of engineering and life sciences, and advance both engineering and life sciences. The projects should focus on high impact transformative methods and technologies. Projects should include methods, models and enabling tools of understanding and controlling living systems; fundamental improvements in deriving information from cells, tissues, organs, and organ systems; new approaches to the design of structures and materials for eventual medical use in the long-term; and novel methods for reducing health care costs through new technologies. The long-term impact of the projects can be related to fundamental understanding of cell and tissue function, effective disease diagnosis and/or treatment, improved health care delivery, or product development.

This initiative will support research projects that implement and test comprehensive service approaches to engage and retain youth and young adults (age 12 - 25 years) from health disparity populations in the HIV Treatment Cascade, which includes diagnosis, linkage to care, engagement in care, retention in care, initiation of antiretroviral therapy (ART), and achievement of viral suppression.